Sinolink: The warm breeze of medical policies arrives first, focusing on the sectors of innovative drugs and generic innovative drugs with high investment opportunities.

In 2024, the pharmaceutical sector continues to face pressure and is searching for a bottom, but long-term demand remains stable, and there are reversal trends in policies, funding, and fundamentals, which is expected to yield excess returns in the pharmaceutical field in 2025.

Zhitong FinanceDec 9 03:14 ET

Guosen's 2025 strategy for csi sws health care index: Innovation leads to industrial upgrade.

Current domestic medical demand continues to upgrade, the macro economy is expected to gradually warm up, and under geopolitical disturbances, the country is likely to increase support for self-controllable initiatives.

Zhitong FinanceDec 9 01:47 ET

Kelong Botai Bio-B (06990.HK) has appointed Zhong Minghui as joint company secretary.

On December 6, Gelonghui announced that Ms. Feng Huishen has resigned as (i) the co-company secretary of the company; (ii) the authorized representative; and (iii) the legal process document agent, effective from January 1, 2025. Ms. Huang Huier has also resigned as the legal process document agent under Section 16 of the Companies Ordinance, effective from January 1, 2025. After Ms. Feng's resignation, the board of directors is pleased to announce that Mr. Zhong Minghui has been appointed as the co-company secretary, authorized representative and legal process document agent under Section 16 of the Companies Ordinance and Listing Rules 19A.13.

Gelonghui FinanceDec 6 05:19 ET

Announcement highlights | Insurers have raised their shareholding in brokerage stocks for the first time in nearly 5 years! New China Life Insurance has increased its shareholding in Haitong Sec; Meitu has liquidated its cryptos for a profit of nearly 80

In November, Country Garden achieved a contract sales amount of approximately 3.01 billion yuan attributable to the company's shareholders; chinares pharma's pharmaceutical commerce can issue a total of 15 billion yuan in asset-backed notes in installments.

cls.cnDec 4 19:11 ET

Hong Kong stocks morning report on December 5: Most china concept stocks fell, Meitu cleared its crypto profits of about 0.571 billion yuan.

The latest Beige Book survey from the Federal Reserve shows a slight increase in economic activity in November. Federal Reserve Chairman Powell stated that the Fed can remain cautious when looking for the neutral interest rate. President Trump selected digital assets advocate Paul Atkins to be the chairman of the U.S. Securities and Exchange Commission, causing a surge in cryptocurrencies and related stocks. The three major U.S. stock indexes hit record highs on Wednesday, while most popular China concept stocks fell.

cls.cnDec 4 18:15 ET

Columbia Biotech-B (06990.HK): The clinical trial application for the new drug SKB500 has been approved by the National Medical Products Administration.

Galenghui December 4th | Cellon Pharmaceutical Group-B (06990.HK) announced that the company has received a clinical trial notification for the clinical trial application of the innovative drug SKB500 developed by the company on December 4, 2024, approved by the Drug Evaluation Center of the National Pharmaceutical Regulatory Agency. SKB500 is a novel ADC drug developed by the company using the OptiDC™ platform technology targeting the biological characteristics of the target, with independent intellectual property rights, demonstrating good efficacy and safety window in preclinical studies, intended for the treatment of advanced solid tumors.

Gelonghui FinanceDec 4 03:44 ET